High dose (HD) IL-2 for metastatic renal cell carcinoma (mRCC) in the targeted therapy era: Extension of OS benefits beyond complete response (CR) and partial response (PR).

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Aung, S; Morse, MA; Wong, MKK; Kaufman, H; Daniels, GA; McDermott, DF

Published Date

  • March 2015

Published In

Volume / Issue

  • 33 / 7_suppl

Start / End Page

  • 423 - 423

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2015.33.7_suppl.423